// App-Quantinova.ai

: Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC).

Researchers

Presenter

  • Simon Yuen Fai Fu

Principal Investigators

  • Elie Ritch

  • Steven Yip

  • Daniel Khalaf

  • Sinja Taavitsainen

  • Matti Annala

  • Gillian Vandekerkhove

  • Igal Kushnir

  • Sebastien J. Hotte

  • Cristiano Ferrario

  • Alexander William Wyatt

  • Kim N. Chi

Medical Centers

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

  • BioMediTech, University of Tampere, Tampere, Finland

  • Vancouver Prostate Centre and Department of Urologic Sciences, Vancouver, BC, Canada

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Juravinski Cancer Centre, Burlington, ON, Canada

  • Segal Cancer Center/Jewish General Hospital, McGill University, Montreal, QC, Canada

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

Locations

  • Canada

  • Finland

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

  • Apoptotic body index

  • Microsatellite instability

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Prednisone

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved